Lacosamide Anfarm

Lacosamide, the active ingredient in Lacosamide Anfarm, is an anticonvulsant presented as an intravenous solution for intravenous use. It is indicated for the treatment of partial‑onset seizures in adults and children, helping to control epileptic activity by stabilizing neuronal membranes.

GNH USA supplies Lacosamide Anfarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with sourcing from the European Union market. The company ensures quality through rigorous testing and compliance with global regulatory standards, and customers benefit from reliable delivery and comprehensive technical support.

Lacosamide is an anticonvulsant used in the management of seizure disorders.

Partial‑onset seizures: reduces the frequency of focal seizures in patients with epilepsy. Adjunctive therapy for refractory focal seizures: improves seizure control when added to existing antiepileptic regimens. Secondary generalized seizures arising from focal onset: helps prevent spread of seizure activity.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: feeling of queasiness or urge to vomit. - Headache: mild to moderate cranial pain. - Fatigue: unusual tiredness or lack of energy. - Blurred vision: temporary visual disturbances. - Somnolence: increased sleepiness.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation or atrial fibrillation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypersensitivity: rash, angioedema, or anaphylaxis. - Suicidal ideation: emergence of thoughts of self‑harm. - Hepatic enzyme elevation: significant increase in liver function tests. - Respiratory depression: difficulty breathing in susceptible individuals.

When prescribing or administering Lacosamide, consider the following precautions.

Renal impairment: monitor renal function and adjust therapy as needed. Cardiac conduction disorders: obtain baseline ECG and observe for PR‑interval changes. Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. Concomitant CNS depressants: may increase sedation and respiratory depression. Alcohol consumption: avoid excessive intake as it may exacerbate dizziness and drowsiness. Store at 2-8°C: keep refrigerated, protect from light, do not freeze, and retain in original packaging.

Lacosamide can interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): may exacerbate PR‑interval prolongation. - Carbamazepine: can reduce lacosamide plasma concentrations. - Other sodium‑channel blockers (e.g., phenytoin): additive effects on cardiac conduction.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): enhanced sedation and respiratory depression. - Alcohol: increased risk of dizziness and somnolence. - Hormonal contraceptives: possible reduction in contraceptive efficacy.